advertisement
advertisement
HANNOVER MESSE 2018, 23 - 27 April
R&D-Project

ULTRAPLACAD

ULTRAsensitive PLAsmonic devices for early CAncer Diagnosis

Logo Scriba Nanotecnologie

Exhibitor

Scriba Nanotecnologie

Exhibitor details
Exhibitor details
Logo ULTRAPLACAD
Logo ULTRAPLACAD
Logo ULTRAPLACAD
Logo ULTRAPLACAD
Development status
Under development
Market introduction
03.2021
Degree of documentation
Well documented
Market orientation
Medium-size market

Product description

ULTRAPLACAD project represents a radical change in colorectal cancer early diagnostics and therapy monitoring, finally reaching the detection of circulating biomarkers in blood (liquid biopsy). The diagnostic test market is expected to reach 670M$ in 2020. The market of Colorectal Cancer diagnostics (CRC) should reach 74M$ in 2020.
Cancer biomarkers, in particular DNA, mRNA and tumour antibodies, circulating in body fluids, have been shown to reflect the pathological process. For this reason, they can be used for cancer diagnosis, prognosis and choice for therapeutic interventions. Biomarker detection is a key aspect to new minimally-invasive diagnostic approaches.
ULTRAPLACAD aims at the development of a novel robust in vitro diagnostic system for early cancer diagnosis, based on molecular analysis of peripheral blood (liquid biopsy).
The project is focused at developing a compact plasmonic-based disposable device with an integrated microfluidic circuit and functionalized nanostructures for the detection of DNA, microRNA and tumor autoantibodies. The aim is to detect these cancer biomarkers circulating in blood with improvement in sensitivity, reduction in cost of platform compared to today s available techniques and analysis time less than 1h.

Product website

Hall 2, Stand B61/2

(Main stand)

Stored items

0

Server communication error: Item could not be saved.